Revealing LIM Domain Transcriptional Complexes that establish and maintain Beta Cell Mass

揭示建立和维持 β 细胞质量的 LIM 结构域转录复合物

基本信息

批准号：
9922287
负责人：
Chad S Hunter
金额：
$ 37.13万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-07-01 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9922287
关键词：
Adult Affect American Apoptosis Appearance Attenuated B-Cell Development B-Lymphocytes Beta Cell Birth Brain Cell Line Cell Lineage Cell Maturation Cell Proliferation Cell Survival Cell Therapy Cell physiology Cells Complex Data Data Set Development Diabetes Mellitus Disease Economics Embryo Endocrine Epidemic Functional disorder Future Gene Expression Regulation Generations Genes Genetic Genetic Transcription Goals Healthcare Hormones Human In Vitro Insulin Islet Cell Islets of Langerhans Knock-out Knowledge LIM Domain Maintenance Mediating Messenger RNA Modeling Molecular Target Multipotent Stem Cells Natural regeneration Neonatal Organogenesis Outcome Pancreas Pathway interactions Patients Phase Protein Binding Domain Proteins Publishing Quality of life Reagent Regulator Genes Reporting Research Role SS DNA BP Structure of beta Cell of islet Testing Transcriptional Regulation Type 2 diabetic Work beta cell replacement blood glucose regulation care burden combat comparative diabetes mellitus therapy diabetic endocrine pancreas development experience genome-wide improved in vivo insight insulin secretion islet knock-down morphometry mouse model next generation next generation sequencing novel pancreas development postnatal preservation progenitor programs promoter protein complex recruit stem cells success transcription factor transcriptomics translational approach

项目摘要

Pancreatic islets of Langerhans contain insulin-secreting β-cells required for maintaining glucose homeostasis. Dysfunction in β-cell activity or survival results in diabetes mellitus, a disease affecting millions of Americans with numbers expected to greatly increase. This is creating an enormous economic and health care burden. A future strategy for improving diabetic outcomes will include cell-based therapies wherein functional β-cells are generated to replenish those lost during diabetes progression. Success will require increasing our understanding of the complex transcriptional programs required for establishing and maintaining β-cells during development and in adults, respectively. My lab and others previously demonstrated that the Islet-1 transcription factor is important for islet cell development and function. Furthermore, Islet-1 activity during late phases of β-cell development requires the interacting transcriptional co-regulator, Ldb1. However, little is known of the comparative target genes and pathways governed by these factors. The complexity of Ldb1-mediated complexes also appears greater than simply through Islet-1. For example, our recently published data suggests that Ldb1/Islet-1 complexes are very large, also containing SSBP3, a co-regulator required for Ldb1 complex activity and stability in vitro. This suggests that SSBP3 is a new player in β-cell development and function. Three complementary Aims will define comparative roles of Ldb1 complexes during islet development, and in adult β-cells. Aim 1 will utilize conditional Ldb1 knockout models to test function in pancreatic endocrine progenitor cells and beyond. We will examine how Ldb1 impacts pancreas marker expression, cell proliferation and survival, endocrine cell identity, and islet function. Aim 2 will employ genome-wide next generation sequencing approaches to assess genes controlled by Ldb1 in endocrine progenitors. Results will be compared to Islet-1, as well as Pdx1 and Ngn3, two critical factors in developing islets. Aim 3 will examine the in vivo function of the novel pancreas regulator, SSBP3, during islet development and in adult β-cell function, as compared with known Ldb1 and Islet-1 roles. This proposal will test our central hypothesis that multiple Ldb1 complexes are required throughout pancreatic organogenesis and in adult β-cell function. My extensive experience studying transcription factor complexes and our readily available in vitro and in vivo reagents, make my lab uniquely suited to executing these Aims. Results reported from this proposal will benefit efforts in developing new molecular targets and cell-based therapies to combat diabetes.

langerhans的胰岛胰岛胰岛素，这些胰岛含量含有胰岛素分泌β细胞，以维持葡萄糖稳态。 β细胞活性或存活的功能障碍导致糖尿病，这种疾病影响了数百万美国人，预计数量将大大增加。这造成了巨大的经济和医疗保健负担。改善糖尿病结局的未来策略将包括基于细胞的疗法，其中生成功能性β细胞以复制糖尿病进展过程中丢失的疗法。成功将需要我们对分别在发育期间和成年人中建立和维持β细胞所需的复杂转录程序的理解增加。我的实验室和其他人以前证明胰岛1转录因子对于胰岛细胞很重要发展和功能。此外，β细胞发育晚期的胰岛1活性需要相互作用的转录共调节剂LDB1。但是，对这些因素控制的比较靶基因和途径知之甚少。 LDB1介导的复合物的复杂性似乎也比简单地通过ISLET-1更大。例如，我们最近发表的数据表明，LDB1/ISLET-1复合物非常大，还包含SSBP3，这是LDB1复合活性和体外稳定性所需的共同调节剂。这表明SSBP3是β细胞开发和功能方面的新玩家。三个完整的目标将定义胰岛发育过程中LDB1复合物的比较作用，以及在成年β细胞中。 AIM 1将利用条件LDB1基因敲除模型来测试胰腺内分泌祖细胞及其他地区的功能。我们将研究LDB1如何影响胰腺标记表达，细胞增殖和生存，内分泌细胞身份和胰岛功能。 AIM 2将采用全基因组的下一代测序方法来评估内分泌祖细胞中LDB1控制的基因。结果将与Islet-1以及PDX1和NGN3进行比较，这是开发胰岛的两个关键因素。与已知的LDB1和ISLET-1角色相比，AIM 3将检查新型胰腺调节剂SSBP3的体内功能，SSBP3和成人β细胞功能。该提案将测试我们的中心假设，即在胰腺器官发生和成人β细胞功能中都需要多个LDB1复合物。我的广泛研究转录因子复合物以及我们随时可以在体外和体内试剂中获得的经验，使我的实验室非常适合执行这些目标。该提案报告的结果将有益于开发新的分子靶标和基于细胞的疗法以对抗糖尿病。